Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CalliSpheres
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Hydrogel Systems → Drug Delivery Systems
- Administration
- Intra-arterial
01
Overview
CalliSpheres are a type of drug-eluting bead (DEB) composed of a polyvinyl alcohol (PVA) hydrogel, specifically engineered for the treatment of hypervascular tumors through transarterial chemoembolization (TACE). Developed by Jiangsu Hengrui Medicine and its subsidiary Suzhou Callisyn Biomedical, these microspheres are designed to be loaded with chemotherapeutic agents, such as doxorubicin, epirubicin, or oxaliplatin, via an ion-exchange mechanism. Once injected into the tumor-feeding arteries, CalliSpheres provide a dual therapeutic effect: they physically occlude the blood vessels to induce tumor ischemia and necrosis, and they simultaneously release the loaded drug in a controlled, sustained manner directly into the tumor tissue. This localized delivery maximizes the intratumoral drug concentration while significantly reducing systemic exposure and associated side effects. CalliSpheres are primarily indicated for hepatocellular carcinoma (HCC) and are also utilized in the management of liver metastases and other hypervascular malignancies.
- Brand names
- CalliSpheres
- Other names
- CalliSpheres MicrospheresCalliSpheres Drug-Eluting Beads
Beyond the preview
Go deeper on CalliSpheres.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CalliSpheres.